<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Mosley, Mary</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Marso, Steven P.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">LEADER Study: Testing the Cardiovascular Safety of Liraglutide</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2013-11-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">14-15</style></pages><abstract><style  face="normal" font="default" size="100%">Liraglutide, an analogue for human glucagon-like peptide 1, is approved for patients with type 2 diabetes mellitus and is associated with HbA1C reductions of 1.0% to 1.5% and moderate weight loss. Diabetes is associated with a 2-fold increased risk of cardiovascular (CV) events. The ongoing Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results - A Long Term Evaluation trial [LEADER; NCT01179048] is evaluating the CV safety of liraglutide, in accordance with requirements of the United States Food and Drug Administration.</style></abstract><number><style face="normal" font="default" size="100%">17</style></number><volume><style face="normal" font="default" size="100%">13</style></volume></record></records></xml>